Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan

BACKGROUND: The impact of gonadotropin-releasing hormone (GnRH) antagonist and agonist (GnRHa) treatment on cardiovascular disease (CVD) risk in prostate cancer (PCa) remains inconclusive due to conflicting findings. We compared the effects of GnRH antagonist and GnRHa treatments on CVD risk in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Yu-Hsuan Joni, Hong, Jian-Hua, Chen, Chun-Kai, Huang, Chao-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638084/
https://www.ncbi.nlm.nih.gov/pubmed/35662291
http://dx.doi.org/10.1038/s41391-022-00555-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638084/
https://www.ncbi.nlm.nih.gov/pubmed/35662291
http://dx.doi.org/10.1038/s41391-022-00555-0

Ejemplares similares